Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066894
Filing Date
2025-05-08
Accepted
2025-05-08 16:01:21
Documents
77
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q alxo-20250331.htm   iXBRL 10-Q 2491476
2 EX-10.1 alxo-ex10_1.htm EX-10.1 116979
3 EX-10.2 alxo-ex10_2.htm EX-10.2 47295
4 EX-10.3 alxo-ex10_3.htm EX-10.3 45703
5 EX-31.1 alxo-ex31_1.htm EX-31.1 18740
6 EX-31.2 alxo-ex31_2.htm EX-31.2 18972
7 EX-32.1 alxo-ex32_1.htm EX-32.1 10874
8 EX-32.2 alxo-ex32_2.htm EX-32.2 10898
  Complete submission text file 0000950170-25-066894.txt   9475825

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alxo-20250331.xsd EX-101.SCH 1117292
80 EXTRACTED XBRL INSTANCE DOCUMENT alxo-20250331_htm.xml XML 1620034
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

EIN.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39386 | Film No.: 25925810
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)